Alnylam Pharmaceuticals (ALNY) Depreciation & Amortization (CF) (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Depreciation & Amortization (CF) data on file, last reported at $13.6 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 5.91% year-over-year to $13.6 million; the trailing twelve-month figure through Mar 2026 stood at $54.8 million (down 4.78% YoY), and the FY2025 full-year result was $55.7 million, down 1.79% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $13.6 million, roughly flat from $13.5 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $15.0 million in Q2 2024 and bottomed at $9.5 million in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $13.6 million (2026), against an average of $13.2 million.
• The widest annual swing landed in 2022, when Depreciation & Amortization (CF) slipped 24.93%; it then soared 48.68% in 2023.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $14.3 million in 2022, then fell by 5.79% to $13.5 million in 2023, then climbed by 5.09% to $14.2 million in 2024, then retreated by 4.67% to $13.5 million in 2025, then increased by 0.35% to $13.6 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $13.6 million (Q1 2026), $13.5 million (Q4 2025), and $13.8 million (Q3 2025), per Business Quant data.

Peer Comparison